Nanotechnology in bladder cancer: Current state of development and clinical practice

Nanomedicine

Volumn 10, Issue 7, 2015, Pages 1189-1201

  Tomlinson, Ben ^a   Lin, Tzu Yin ^a   Dall'Era, Marc ^a   Pan, Chong Xian ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

bladder cancer; nanoparticle; photodynamic diagnosis; photodynamic therapy

Indexed keywords

GLYCOLIC ACID; GOLD NANOPARTICLE; MAGNETIC NANOPARTICLE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ANTINEOPLASTIC AGENT; NANOPARTICLE; PHOTOSENSITIZING AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BCG VACCINATION; BLADDER CANCER; BLADDER IRRIGATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCREENING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG RELEASE; DRUG RETENTION; GOLD STANDARD; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; LYMPH NODE; LYMPH NODE METASTASIS; NANOTECHNOLOGY; NONMYOINVASIVE BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; WHITE LIGHT; ANIMAL; BLADDER; CHEMISTRY; DRUG EFFECTS; NANOMEDICINE; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84929091576     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.212     Document Type: Article

References (89)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl. 1), 4-34 (2005).
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
3. Fleming JD, Cooper JS, Jenson DE, Al E. AJCC (American Joint Committee on Cancer) Cancer Staging Manuel (5th Edition) . Lippincott-Raven, PA, USA (1997).
4. Morgan TM, Clark PE. Bladder cancer. Curr. Opin. Oncol. 22(3), 242-249 (2010).
5. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 13(6), 1404-1408 (1995).
6. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol. 141(1), 22-29 (1989).
7. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 158(1), 62-67 (1997).
8. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol. 163(3), 761-767 (2000).
9. Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3), 549-553 (2006).
10. Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J. Urol. 27(3), 295-300 (2009).
11. Barocas DA, Globe DR, Colayco DC et al. Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv. Urol. 2012, 421709 (2012).
12. Avis NE, Deimling GT. Cancer survivorship and aging. Cancer 113(12 Suppl.), 3519-3529 (2008).
13. Avis NE, Smith KW, Mcgraw S, Smith RG, Petronis VM, Carver CS. Assessing quality of life in adult cancer survivors (QLACS). Qual. Life Res. 14(4), 1007-1023 (2005).
14. Von Der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
15. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol. Sci. Appl. 1, 17-32 (2008).
16. Ghosh S, Ucer KB, D'agostino R Jr et al. Non-covalent assembly of meso-tetra-4-pyridyl porphine with singlestranded DNA to form nano-sized complexes with hydrophobicity-dependent DNA release and anti-tumor activity. Nanomedicine 10(2), 451-461 (2014).
17. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug. Discov. 7(9), 771-782 (2008).
18. Janib SM, Moses AS, Mackay JA. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62(11), 1052-1063 (2010).
19. Bastakoti BP, Wu KC, Inoue M, Yusa S, Nakashima K, Yamauchi Y. Multifunctional core-shell-corona-type polymeric micelles for anticancer drug-delivery and imaging. Chemistry 19(15), 4812-4817 (2013).
20. Choi HK, Gwyther J, Manners I, Ross CA. Square arrays of holes and dots patterned from a linear ABC triblock terpolymer. ACS Nano 6(9), 8342-8348 (2012).
21. Zhang H, Aina OH, Lam KS et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. 30(5), 635-645 (2012).
22. Lin TY, Li YP, Zhang H et al. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond.) 8(8), 1239-1251 (2013).
23. Eissa S, Shawky SM, Matboli M, Mohamed S, Azzazy HM. Direct detection of unamplified hepatoma upregulated protein RNA in urine using gold nanoparticles for bladder cancer diagnosis. Clin. Biochem. 47(1-2), 104-110 (2014).
24. Nakamura T, Fukiage M, Higuchi M et al. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J. Control. Release 176c, 44-53 (2013).
25. Bilensoy E, Sarisozen C, Esendagli G et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int. J. Pharm. 371(1-2), 170-176 (2009).
26. Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother. Pharmacol. 44(3), 241-248 (1999).
27. Chang LC, Wu SC, Tsai JW, Yu TJ, Tsai TR. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Int. J. Pharm. 376(1-2), 195-203 (2009).
28. Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S. Photodynamic therapy of cancer. Basic principles and applications. Clin. Transl. Oncol. 10(3), 148-154 (2008).
29. Qian HS, Guo HC, Ho PC, Mahendran R, Zhang Y. Mesoporous-silica-coated up-conversion fluorescent nanoparticles for photodynamic therapy. Small 5(20), 2285-2290 (2009).
30. Li Y, Xiao W, Xiao K et al. Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH Values and cis-diols. Angew. Chem. Int. Ed. Engl. 51, 2864-2869 (2012).
31. Mugabe C, Matsui Y, So AI et al. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin. Cancer Res. 17(9), 2788-2798 (2011).
32. Lin TY, Zhang H, Wang S et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancerspecific ligand. Mol. Cancer 10(1), 9 (2011).
33. Lin TY, Zhang H, Luo J et al. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomedicine 7, 2793-2804 (2012).
34. Pirollo KF, Rait A, Zhou Q et al. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin. Cancer Res. 14(7), 2190-2198 (2008).
35. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J. Urol. 174(6), 2134-2137 (2005).
36. Yuan H, Qiu J, Liu L et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with nonmuscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS ONE 8(9), e74142 (2013).
37. Ray ER, Chatterton K, Khan MS et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. 105(6), 789-794 (2010).
38. Lopez A, Liao JC. Emerging endoscopic imaging technologies for bladder cancer detection. Curr. Urol. Rep. 15(5), 406 (2014).
39. Yan X, Al-Hayek S, Huang H, Zhu Z, Zhu W, Guo H. Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: a preliminary investigation. Scand. J. Urol. 47(2), 145-151 (2013).
40. Olivo M, Fu CY, Raghavan V, Lau WK. New frontier in hypericin-mediated diagnosis of cancer with current optical technologies. Ann. Biomed. Eng. 40(2), 460-473 (2012).
41. Lin T-Y, Li Y, Zhang H, Lam K, Pan C-X. Bladder cancer targeting nanomicelle. Presented at: 2013 40th Annual Meeting & Exposition of the Controlled Release Society. HI, USA, 21-24 July 2013.
42. Nossier AI, Eissa S, Ismail MF, Hamdy MA, Azzazy HM. Direct detection of hyaluronidase in urine using cationic gold nanoparticles: a potential diagnostic test for bladder cancer. Biosens. Bioelectron 54, 7-14 (2014).
43. Martin DT, Steinbach JM, Liu J et al. Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. Mol. Cancer Ther. 13(1), 71-81 (2014).
44. Martin DT, Hoimes CJ, Kaimakliotis HZ et al. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine 9(8), 1124-1134 (2013).
45. Kang MR, Yang G, Place RF et al. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res. 72(19), 5069-5079 (2012).
46. Erdogar N, Iskit AB, Mungan NA, Bilensoy E. Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours. J. Microencapsul. 29(6), 576-582 (2012).
47. Chen G, He Y, Wu X, Zhang Y, Luo C, Jing P. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer. Braz. J. Med. Biol. Res. 45(8), 771-776 (2012).
48. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxelloaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 10(22), 7677-7684 (2004).
49. Lu Z, Yeh TK, Wang J et al. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J. Urol. 185(4), 1478-1483 (2011).
50. Tsallas A, Jackson J, Burt H. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Cancer Chemother. Pharmacol. 68(2), 431-444 (2011).
51. Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. Development of copolymers of poly(d,l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf. B Biointerfaces 16(1-4), 161-171 (1999).
52. Mugabe C, Hadaschik BA, Kainthan RK et al. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int. 103(7), 978-986 (2009).
53. Mugabe C, Matsui Y, So AI et al. In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer. Biomacromolecules 12(4), 949-960 (2011).
54. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005).
55. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369(18), 1691-1703 (2013).
56. Mckiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J. Urol. 186(2), 448-451 (2011).
57. Bassi PF, Volpe A, D'agostino D et al. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a Phase I study. J. Urol. 185(2), 445-449 (2011).
58. Huang C, Neoh KG, Xu L, Kang ET, Chiong E. Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. Biomacromolecules 13(8), 2513-2520 (2012).
59. Men K, Liu W, Li L et al. Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermosensitive hydrogel composite system. Nanoscale 4(20), 6425-6433 (2012).
60. Derycke AS, Kamuhabwa A, Gijsens A et al. Transferrinconjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J. Natl Cancer Inst. 96(21), 1620-1630 (2004).
61. Guo H, Qian H, Idris NM, Zhang Y. Singlet oxygeninduced apoptosis of cancer cells using upconversion fluorescent nanoparticles as a carrier of photosensitizer. Nanomedicine 6(3), 486-495 (2010).
62. Luo DS, Mi QW, Meng XJ, Gao Y, Dai YP, Deng CH. Synergetic killing effects of external magnetic fields combined with porphyrin-dextran magnetic nanoparticles on the human bladder cancer cells. Beijing Da Xue Xue Bao 44(4), 524-527 (2012).
63. Cheng FY, Chen CT, Yeh CS. Comparative efficiencies of photothermal destruction of malignant cells using antibodycoated silica@Au nanoshells, hollow Au/Ag nanospheres and Au nanorods. Nanotechnology 20(42), 425104 (2009).
64. Szlachcic A, Pala K, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J. FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int. J. Nanomedicine 7, 5915-5927 (2012).
65. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003).
66. Sternberg CN, De Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european organization for research and treatment of cancer protocol no. 30924. J. Clin. Oncol. 19(10), 2638-2646 (2001).
67. Deserno WM, Harisinghani MG, Taupitz M et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran- 10-enhanced MR imaging. Radiology 233(2), 449-456 (2004).
68. Triantafyllou M, Studer UE, Birkhauser FD et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur. J. Cancer 49(3), 616-624 (2013).
69. Thoeny HC, Triantafyllou M, Birkhaeuser FD et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur. Urol. 55(4), 761-769 (2009).
70. Montie JE. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. J. Urol. 174(3), 870-871 (2005).
71. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986).
72. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207 (2001).
73. Luo J, Xiao K, Li Y et al. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug. Chem. 21(7), 1216-1224 (2010).
74. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8(5), 1038-1044 (2002).
75. Cucinotto I, Fiorillo L, Gualtieri S et al. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J. Drug Deliv. 2013, 905091 (2013).
76. Ko YJ, Canil CM, Mukherjee SD et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, Phase 2 study. Lancet Oncol. 14(8), 769-776 (2013).
77. Li Y, Xiao K, Luo J et al. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials 32(27), 6633-6645 (2011).
78. Xiao K, Luo J, Fowler WL et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30(30), 6006-6016 (2009).
79. Li Y, Xiao K, Luo J, Lee J, Pan S, Lam KS. A novel sizetunable nanocarrier system for targeted anticancer drug delivery. J. Control. Release 144(3), 314-323 (2010).
80. Xiao K, Li Y, Luo J et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32(13), 3435-3446 (2011).
81. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS. PEGoligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J. Control. Release 155(2), 272-281 (2011).
82. Zhang H, Luo J, Li Y et al. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine 8(7),1116-1124 (2012).
83. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 10(18), 2941-2952 (1999).
84. Yang Y-H, Liu C-H, Liang Y-H, Lin F-H, Wu KCW. Hollow mesoporous hydroxyapatite nanoparticles (hmHANPs) with enhanced drug loading and pH-responsive release properties for intracellular drug delivery. J. Mater. Chem. B 1(19), 2447-2450 (2013).
85. Lian H-Y, Hu M, Liu C-H, Yamauchi Y, Wu KCW. Highly biocompatible, hollow coordination polymer nanoparticles as cisplatin carriers for efficient intracellular drug delivery. Chem. Commun. 48(42), 5151-5153 (2012).
86. Huxford RC, Della Rocca J, Lin W. Metal-organic frameworks as potential drug carriers. Curr. Opin. Chem. Biol. 14(2), 262-268 (2010).
87. Bastakoti BP, Hsu YC, Liao SH et al. Inorganic-organic hybrid nanoparticles with biocompatible calcium phosphate thin shells for fluorescence enhancement. Chem. Asian J. 8(6), 1301-1305 (2013).
88. Liang YH, Liu CH, Liao SH et al. Cosynthesis of cargoloaded hydroxyapatite/alginate core-shell nanoparticles (HAP@Alg) as pH-responsive nanovehicles by a pre-gel method. ACS Appl. Mater. Interfaces 4(12), 6720-6727 (2012).
89. Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 41(7), 2590-2605 (2012).